Lactamase β reprograms lipid metabolism to inhibit the progression of endometrial cancer through attenuating MDM2-mediated p53 ubiquitination and degradation
Archives of Biochemistry and Biophysics · 2025
DOI: 10.1016/j.abb.2024.110287 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2025. Verfasst von Ting Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital…. Hauptthemen laut MEDLINE: Lipid Metabolism, Ubiquitination, Tumor Suppressor Protein p53, Proto-Oncogene Proteins c-mdm2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Medical and Health Science and Technology Development Project of Shandong Province.
Abstract (Originalsprache)
BACKGROUND: Lactamase β (LACTB) inhibits the metastasis and progression of multiple malignant tumors. However, little is known about its role in endometrial cancer (EC). Our study aimed to investigate the function and potential molecular mechanism of LACTB in modulating EC progression. METHODS: LACTB expression was measured via immunohistochemistry staining, Western blot and qRT-PCR. The role of LACTB in EC was investigated both in vivo and in vitro by employing xenograft mice models and using colony formation, EdU, and Transwell assays, along with flow cytometric analysis. In addition, to assess LACTB function on lipid metabolism, lipid droplets in EC cells were labeled with Nile red. Western blot, immunofluorescence staining, co-immunoprecipitation, ubiquitination assay, and cycloheximide chase assay and rescue experiments were performed to confirm the interaction between LACTB, p53, and MDM2 in EC. RESULTS: LACTB expression was downregulated in EC. LACTB inhibited the malignant phenotypes and reprogramed lipid metabolism in EC cells. Moreover, LACTB significantly upregulated p53 by attenuating the MDM2-mediated ubiquitination and degradation of p53. Besides, LACTB silencing facilitated the malignant phenotypes and reprogramed lipid metabolism in EC cells; this was reversed with p53 overexpression. LACTB knockdown facilitated EC progression via downregulating p53 in vivo. CONCLUSION: LACTB repressed EC cell proliferation and metastasis, and reprogramed lipid metabolism via attenuating the MDM2-mediated ubiquitination and degradation of p53.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Laboratory of Laparoscopic Technology, The First Affiliated Hospital…
- Department of Obstetrics and Gynecology, Weihaiwei People's Hospital, Weihai, 264299, Shandong, China.
Förderung
- Medical and Health Science and Technology Development Project of Shandong Province
Zitieren
APA
Zhou, T., Li, X., Zhao, F., Zhou, J., & Sun, B. (2025). Lactamase β reprograms lipid metabolism to inhibit the progression of endometrial cancer through attenuating MDM2-mediated p53 ubiquitination and degradation. Archives of Biochemistry and Biophysics. https://doi.org/10.1016/j.abb.2024.110287
Vancouver
Zhou T, Li X, Zhao F, Zhou J, Sun B. Lactamase β reprograms lipid metabolism to inhibit the progression of endometrial cancer through attenuating MDM2-mediated p53 ubiquitination and degradation. Archives of Biochemistry and Biophysics. 2025. doi:10.1016/j.abb.2024.110287
BibTeX
@article{Zhou2025,
author = {Zhou, Ting and Li, Xiaorong and Zhao, Fangfang and Zhou, Jing and Sun, Binghui},
title = {Lactamase β reprograms lipid metabolism to inhibit the progression of endometrial cancer through attenuating MDM2-mediated p53 ubiquitination and degradation},
journal = {Archives of Biochemistry and Biophysics},
year = {2025},
doi = {10.1016/j.abb.2024.110287}
}
EUVIMED